# Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

> **NCT02369458** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 48 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma, Head and Neck

## Interventions

- **DRUG:** Mitomycin-C
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT02369458
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-14
- **Primary completion:** 2022-06-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02369458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02369458, "Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02369458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*